Form 4: Provectus CEO Converts Note to Preferred Stock

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into 37,744 shares of Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted an 8% unsecured convertible promissory note (the '2025 Note') into Series D-1 Convertible Preferred Stock.
• The conversion occurred on January 30, 2026, at a price of $2.862 per share of Series D-1 Convertible Preferred Stock.
• The 2025 Note, with an outstanding principal and interest of $100,000, automatically converted into 37,744 shares of Series D-1 Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless converted earlier.
• Following this transaction, Edward Pershing beneficially owns 2,578,867 shares of Common Stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It's a pre-planned conversion of a debt instrument into equity by a key insider, which can be seen as a sign of continued commitment, though it also introduces future dilution.

Positives

• The conversion by the CEO demonstrates continued commitment and an indirect increase in his equity stake in the company.

Negatives

• The conversion of preferred stock into common stock by June 20, 2026, will result in dilution for existing common shareholders, as 37,744 preferred shares will convert into 377,440 common shares.

Risks

• Future dilution of common stock due to the automatic conversion of Series D-1 Convertible Preferred Stock by June 20, 2026.
• The value of the common stock could be negatively impacted by the increased share count upon conversion.

Future Outlook

The 37,744 shares of Series D-1 Convertible Preferred Stock acquired by Edward Pershing will automatically convert into 377,440 shares of Common Stock on June 20, 2026, unless converted earlier.

Industry Context

StockSavvy.ai notes that insider conversions of convertible notes are a routine part of capital structure management, particularly for smaller biopharmaceutical companies like Provectus. While this specific transaction is a pre-planned conversion, it highlights the ongoing financial activities within the company and the CEO's continued equity interest.

Related Party Transactions

• Edward Pershing, CEO and Director, converted an 8% unsecured convertible promissory note (the '2025 Note') issued by Provectus Biopharmaceuticals, Inc. into Series D-1 Convertible Preferred Stock. This transaction involves a direct financial dealing between a key executive and the company.

Stakeholder Impact

• Common shareholders face potential future dilution as the 37,744 shares of Series D-1 Convertible Preferred Stock, convertible into 377,440 shares of common stock, will automatically convert by June 20, 2026.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, Insider Transaction, Form 4, Convertible Note, Preferred Stock, CEO, Equity Conversion, Dilution